These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1904426)

  • 1. Augmentation by tumor necrosis factor alpha of the systemic therapeutic effect of lymphokine-activated killer cells in adoptive immunotherapy of murine tumor.
    Kato K; Tanabe T; Agatsuma T; Suzuki S; Nitanai H; Hashimoto Y
    Jpn J Cancer Res; 1991 Apr; 82(4):464-9. PubMed ID: 1904426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y
    Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
    Lee K; O'Donnell RW; Cockett AT
    J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
    Teichmann JV; Ludwig WD; Thiel E
    Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.
    Puri RK; Leland P
    Clin Exp Immunol; 1991 Aug; 85(2):317-25. PubMed ID: 1713814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
    Gazit Z; Weiss DW; Shouval D; Yechezkeli M; Schirrmacher V; Notter M; Walter J; Kedar E
    Cancer Immunol Immunother; 1992; 35(2):135-44. PubMed ID: 1596937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells.
    Rodolfo M; Salvi C; Bassi C; Rovetta G; Melani C; Colombo MP; Parmiani G
    Nat Immun Cell Growth Regul; 1991; 10(6):308-19. PubMed ID: 1787836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice.
    Ettinghausen SE; Puri RK; Rosenberg SA
    J Natl Cancer Inst; 1988 Apr; 80(3):177-88. PubMed ID: 3258039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-alpha potentiation of the lymphokine-activated killer response of murine thymus cells.
    Ujházy P; Maccubbin D; Eppolito C; Mihich E; Ehrke MJ
    Lymphokine Cytokine Res; 1994 Apr; 13(2):99-106. PubMed ID: 8061121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation of murine lymphokine-activated killer cell cytotoxicity by beta-cyclodextrin-benzaldehyde.
    Kuroki Y; Ochiai H; Kurokawa M; Niwayama S; Kishimoto C; Tazawa K; Fujimaki M
    J Cancer Res Clin Oncol; 1991; 117(2):109-14. PubMed ID: 2007609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
    Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
    Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmented accumulation of transferred lymphokine-activated killer (LAK) cells at murine tumor sites through production of LAK-attractant facilitated by chemotherapy.
    Hosokawa M; Wakizaka Y; Kuramitsu Y; Micallef M; Togashi Y; Kobayashi H
    Tohoku J Exp Med; 1992 Oct; 168(2):413-6. PubMed ID: 1306328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma.
    Saito H; Ando S; Morishita N; Lee KM; Dator D; Dy D; Shigemura K; Adhim Z; Nibu K; Fujisawa M; Shirakawa T
    Anticancer Res; 2014 Jul; 34(7):3365-70. PubMed ID: 24982341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid.
    Lin TH; Chu TM
    Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of TNF-alpha and IFN-alpha on the proliferation and cytotoxicity of lymphokine-activated killer cells in patients with bladder cancer.
    Wang Z; Cheng Y; Zheng R; Qin D; Liu G
    Chin Med J (Engl); 1997 Mar; 110(3):180-3. PubMed ID: 9594335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of the effect of lithium on lymphokine-activated killer cell activity and its antitumor growth.
    Wu Y; Cai D
    Proc Soc Exp Biol Med; 1992 Dec; 201(3):284-8. PubMed ID: 1332071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.